Isoflurane - Product Information
|Form:||Liquid solution, Inhaler|
Summary Product Information
|Route of |
|Dosage Form / |
|Inhalation||volatile liquid / |
> 99.9% v/v
Indications and Clinical Use
ISOFLURANE (isoflurane) is indicated for:
- induction and maintenance of general anesthesia. Adequate data have not been developed to establish its application in obstetrical anesthesia.
Geriatrics (> 65 years of age)
The minimum alveolar concentration (MAC) of isoflurane decreases with increasing patient age. The dose should be adjusted accordingly. For details, see DOSAGE AND ADMINISTRATION, Recommended Dose and Dosage Adjustment.
Pediatrics (< 18 years of age):
ISOFLURANE is not indicated in children.
- Patients with known sensitivity to ISOFLURANE (isoflurane) or the other halogenated agents.
- Patients in whom liver dysfunction, jaundice or unexplained fever, leucocytosis, or eosinophilia has occurred after a previous halogenated anesthetic administration (see WARNINGS AND PRECAUTIONS).
- Patients with known or suspected genetic susceptibility to malignant hyperthermia, or in patients with a known or suspected history of malignant hyperthermia.
- Patients when general anesthesia is contraindicated.
Warnings and Precautions
Serious Warnings and Precautions
ISOFLURANE(isoflurane) should be administered only by persons trained in the administration of general anesthesia.
Facilities for maintenance of a patent airway, artificial ventilation, oxygen enrichment, and circulatory resuscitation must be immediately available.
ISOFLURANEmay trigger Malignant Hyperthermia in susceptible individuals and fatal outcomes have been reported (see WARNINGS AND PRECAUTIONS, Endocrine and Metabolism, Malignant Hyperthermia).
ISOFLURANEmay lead to Perioperative Hyperkalemia in patients with neuromuscular disorders (see WARNINGS AND PRECAUTIONS, Endocrine and Metabolism, Perioperative Hyperkalemia).
Deliver ISOFLURANE from a vaporizer specifically designed and designated for use with ISOFLURANE. Monitoring of end-tidal concentration may be considered.
Safe Use of CO2 Absorbents
Rare cases of extreme heat, smoke and/or spontaneous fire in the anesthesia machine have been reported during administration of general anesthesia with drugs in this class when used in conjunction with desiccated CO2 absorbents, specifically those containing potassium hydroxide (e.g., Baralyme). When a clinician suspects that the CO2 absorbent may be desiccated, it should be replaced before administration of ISOFLURANE. The colour indicator of most CO2 absorbents does not necessarily change as a result of desiccation. Therefore, the lack of significant colour change should not be taken as an assurance of adequate hydration. CO2 absorbents should be replaced routinely regardless of the state of the colour indicator.
ISOFLURANE causes a dose-dependent reduction in systemic vascular resistance and blood pressure. Particular care must be taken when selecting the dosage for patients who are hypovolemic, hypotensive, or otherwise hemodynamically compromised, for example due to concomitant medications. Excessive decreases in blood pressure may be related to depth of anesthesia and respond to reducing the inspired concentration of ISOFLURANE.
In patients with coronary artery disease, maintenance of normal hemodynamics is important in order to avoid myocardial ischemia. ISOFLURANE can cause dose-dependent coronary vasodilation and has been shown to divert blood from collateral-dependent myocardium to normally perfused areas in an animal model (“coronary steal”). The extent to which coronary steal occurs in patients with steal-prone coronary anatomy is unclear. ISOFLURANE should be used with caution in such patients.
Caution should be exercised when administering ISOFLURANE to patients at risk for QT prolongation. ISOFLURANE can prolong the QT interval. This effect is exacerbated by some of the patient’s disease conditions or concomitant peri-operative medications. Reports of QT prolongation, associated with torsades de pointes (in exceptional cases, fatal), have been received.
Endocrine and Metabolism
In susceptible individuals, ISOFLURANE anesthesia may trigger a skeletal muscle hypermetabolic state leading to high oxygen demand and the clinical syndrome known as malignant hyperthermia. The syndrome includes features such as high core body temperature, muscle rigidity, tachycardia, tachypnea, cyanosis, arrhythmias, and unstable blood pressure. An increase in overall metabolism may be reflected in an elevated temperature (which may rise rapidly early or late in the case, but usually is not the first sign of augmented metabolism) and an increased usage of the CO2 absorption system (hot canister). PaO2 and pH may decrease, and hyperkalemia and a base deficit may appear. See CONTRAINDICATIONS.
Treatment includes discontinuance of ISOFLURANE, administration of intravenous dantrolene sodium, and application of supportive therapy. Such therapy includes vigorous efforts to restore body temperature to normal, respiratory and circulatory support as indicated, and management of electrolyte-fluid-acid-base derangement. Renal failure may appear later, and urine flow should be sustained if possible.
Use of inhaled anesthetic agents has been associated with rare increases in serum potassium levels that have resulted in cardiac arrhythmias and death in pediatric patients during the postoperative period. Patients with latent as well as overt neuromuscular disease, particularly Duchenne muscular dystrophy, appear to be most vulnerable. Concomitant use of succinylcholine has been associated with most, but not all, of these cases. These patients also experienced significant elevations in serum creatine kinase levels and, in some cases, changes in urine consistent with myoglobinuria. Despite the similarity in presentation to malignant hyperthermia, none of these patients exhibited signs or symptoms of muscle rigidity or hypermetabolic state. Early and aggressive intervention to treat the hyperkalemia and resistant arrhythmias is recommended, as is subsequent evaluation for latent neuromuscular disease.
Caution should be exercised in administering general anesthesia, including ISOFLURANE, to patients with mitochondrial disorders.
ISOFLURANE is contraindicated in patients in whom liver dysfunction, jaundice or unexplained fever, leucocytosis, or eosinophilia has occurred after a previous halogenated anesthetic administration.
Cases of mild, moderate, and severe postoperative hepatic dysfunction or hepatitis with or without jaundice, including fatal hepatic necrosis and hepatic failure, have been reported with Isoflurane. As with other halogenated anesthetics, ISOFLURANE may cause sensitivity hepatitis in patients who have been sensitized by previous exposure to halogenated anesthetics (see CONTRAINDICATIONS and ADVERSE REACTIONS). Therefore, appropriate alternative anesthetic agent(s) should be considered, this is especially important in patients with pre-existing hepatic conditions.
Although the mechanism by which this occurs is still unclear, data from studies on halothane suggests that metabolism by cytochrome P450 2E1 (CYP2E1) catalyzes formation of trifluoroacetylated haptens, which may be implicated as target antigens in the mechanism of halothane-induced hepatitis. Although other halogenated anesthetics are believed to be metabolized to a much lesser degree by the CYP2E1 system (20% by halothane compared to 0.2% isoflurane), the reported hepatic injuries share similarities with that associated with halothane.
In patients with pre-existing hepatic abnormalities or under treatment with drugs known to cause hepatic abnormalities, clinical judgment should be exercised and appropriate alternative general anesthesia should be considered. Specialized care is recommended when a patient presents with any postoperative hepatic dysfunction after receiving a halogenated inhalational anesthetic.
ISOFLURANEmay increase cerebral blood flow and hence cerebrospinal fluid pressure (ICP) and, therefore, should be used with special care in patients with elevated cerebrospinal fluid pressure. In patients with or at risk for elevations of ICP, ISOFLURANE should be administered cautiously and in conjunction with ICP-reducing measures (e.g. optimized hyperventilation).
ISOFLURANE inhibits spontaneous respiration, which is enhanced with concurrent use of other inhalational and intravenous anesthetics. Respiration must be closely monitored and supported by assisted or controlled ventilation when necessary. Excessive respiratory depression may be related to depth of anesthesia and responds to decreasing the inspired concentration of ISOFLURANE.
ISOFLURANE, as well as other general anesthetics, may cause a slight decrease in cognitive function for two to four days following anesthesia. As with other anesthetics, small changes moods and symptoms may persist for up to six days after administration.
Patients should be advised that performance of activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, may be impaired for some time after general anesthesia. See DRUG INTERACTIONS, Drug-Lifestyle Interactions, Effects on Ability to Drive and Use Machines.
Allergic-type hypersensitivity reactions, including anaphylaxis, have been reported with ISOFLURANE. Manifestations of such reactions have included hypotension, rash, difficulty breathing and cardiovascular collapse. Symptomatic management, as appropriate, is recommended as per standard of care.
ISOFLURANE exerts a relaxant effect on uterine smooth muscle. Blood loss during intrauterine procedures is increased when halogenated agents such as ISOFLURANE are used for anesthesia.
Safe use in pregnancy has not been established. Reproduction studies have been performed in rats and mice after repeated exposures to anesthetic concentrations of isoflurane and have revealed no evidence of impaired fertility or harm to the fetus due to isoflurane. There are, however, no adequate and well controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if the benefit outweighs the potential risk.
Women in Labour and Delivery
Safety and efficacy of ISOFLURANE administration during labour and vaginal delivery have not been adequately studied. ISOFLURANE should not be used unless the potential benefit justifies the potential risk.
The use of ISOFLURANE as part of general anesthesia for elective cesarean section has been described in the literature. ISOFLURANE should be used only if the potential benefit justifies the potential risk.
ISOFLURANE exerts a relaxant effect on uterine smooth muscle. This can lead to increased blood loss in situations where uterine muscle contraction aids hemostasis, such as in obstetric surgery and in patients undergoing intrauterine procedures.
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when ISOFLURANEis administered to a nursing woman.
Pediatrics (< 18 of age)
ISOFLURANEis not indicated in children.
Geriatrics (> 65 years of age)
As with other agents, lesser concentrations of ISOFLURANEare normally required to maintain surgical anesthesia in elderly patients. See (DOSAGE AND ADMINISTRATION, Recommended Dose and Dosage Adjustment, Geriatrics).
Monitoring and Laboratory Tests
Blood bilirubin is mildly elevated postoperatively in some cases. Elevated glucose and white blood cell counts have been observed intraoperatively. In diabetic patients, the possible exacerbation of hyperglycemia should be considered.
Transient increases in serum creatinine with decrease in BUN, serum cholesterol and alkaline phosphatase have been observed.
Adverse Drug Reaction Overview
Adverse reactions encountered in the administration of ISOFLURANE are in general dose dependent extensions of pharmacophysiologic effects and include respiratory depression, hypotension and arrhythmias. Potential serious undesirable effects include malignant hyperthermia, anaphylactic reactions, hyperkalemia, elevated serum creatine kinase, myoglobinuria and liver adverse reactions (please refer to Post-Market Adverse Drug Reactions). Shivering, nausea, vomiting ileus, agitation and delirium have been observed in the postoperative period.
Cardiac arrest has been observed with general inhalation anesthetic drugs including ISOFLURANE.
Clinical Trial Adverse Drug Reactions
Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.
Induction of anesthesia with ISOFLURANEin 20 unpremedicated patients was associated with salivation (5), excitement (11), coughing or breath-holding (12), and laryngospasm (3).
The most common adverse events observed during the recovery from anesthesia in a clinical trial (N=100) are presented in Table 1.
|Body as a Whole|
|Excitement and delirium||6%|
In one pivotal clinical trial (including 204 patients), shivering was seen in only 4 patients (2%) following surgery. Nausea and/or vomiting occurred in 12 of 71 males (17%) and in 37 of 133 females (28%). The overall incidence during the first 24 hours was 24% and, of these, one-third had recurrent symptoms.
Abnormal Hematologic and Clinical Chemistry Findings
Transient increases in blood bilirubin, blood glucose and serum creatinine with decrease in BUN, serum cholesterol and alkaline phosphatase have been observed.
Elevation of SGOT, LDH and bilirubin with or without jaundice have been reported in the post-operative period following ISOFLURANEanesthesia in some patients.
Elevated glucose and white blood cell counts have been observed intraoperatively. In diabetic patients, the possible exacerbation of hyperglycemia should be considered.
Minimally raised levels of serum inorganic fluoride occur during and after ISOFLURANE anesthesia, due to biodegradation of the agent. It is unlikely that the low levels of serum inorganic fluoride observed could cause renal toxicity, as these are well below the proposed threshold levels for kidney toxicity.
Post-Market Adverse Drug Reactions
The following adverse reactions have been observed during ISOFLURANE (isoflurane) administration:
- Malignant hyperthermia (see WARNINGS AND PRECAUTIONS), including fatalities
- Hyperkalemia, elevated serum creatine kinase, and myoglobinuria (see WARNING AND PRECAUTIONS)
- Hypotension and respiratory depression
- Postoperative ileus, shivering, nausea and vomiting
- Elevation of the white blood cell count (even in the absence of surgical stress)
- Delirium, hallucinations, agitation and hiccups
- Electroencephalographic changes and convulsions
Cardiac arrest, bradycardia and tachycardia have been observed with general inhalation anesthetic drugs including ISOFLURANE.
Reports of QT prolongation, associated with torsades de pointes (in exceptional cases, fatal), have been received.
Bronchospasm and laryngospasm due to airway irritation have been reported with volatile anesthetics during inhalation.
ISOFLURANE, like other inhalation agents, has relaxant effects on the uterus with the potential for uterine bleeding.
Reports demonstrate that ISOFLURANEcan produce hepatic injury ranging from mild transient increases of liver enzymes to fatal hepatic necrosis in very rare instances.
Rare reports of hypersensitivity (including dermatitis contact, rash, dyspnoea, wheezing, chest discomfort, swelling face, or anaphylactic reaction) have been received, especially in association with long-term occupational exposure to inhaled anesthetic agents, including ISOFLURANE. These reactions have been confirmed by clinical testing (e.g., methacholine challenge). The etiology of anaphylactic reactions experienced during inhalational anesthetic exposure is, however, unclear because of the exposure to multiple concomitant drugs, many of which are known to cause such reactions.
The following reactions have been reported following occupational exposure to isoflurane: dyspnea, bronchospasm, stridor, cough, dizziness, paresthesia, hepatic reactions, flushing, rash, contact dermatitis, erythema, periorbital edema, eye irritation, conjunctival hyperemia, and headache.
|Serious Drug Interactions |
In patients with latent as well as overt muscular dystrophies, particularly Duchenne Muscular Dystrophy, concomitant use with succinylcholine is associated with hyperkalemia and cardiac arrhythmias (see WARNINGS AND PRECAUTIONS).
ISOFLURANE potentiates all commonly used muscle relaxants; the effect being most profound with the non-depolarizing type. Therefore, less than the usual amounts of such agents should be used.
|Benzodiazepines||↓ MAC of|
|Benzodiazepines would be expected to decrease the MAC of ISOFLURANE in the same manner as with other inhalational anesthetics.|
|Calcium antagonists||ISOFLURANE may lead to marked hypotension in patients treated with calcium antagonists, in particular dihydropyridine derivatives.|
Caution should be exercised when calcium antagonists are used concomitantly with inhalation anesthetics due to the risk of additive negative inotropic effect.
|Inducers of CYP2E1||Concomitant use of ISOFLURANE and isoniazid can increase the risk of potentiation of the hepatotoxic effects.|
Medicinal products and compounds that increase the activity of cytochrome P450 isoenzyme CYP2E1, such as isoniazid and alcohol, may increase the metabolism of ISOFLURANE and lead to significant increases in plasma fluoride concentrations. Moreover, CYP2E1 metabolic pathways may be involved in the rare hepatotoxic effects observed with halogenated anesthetics, therefore, a concomitant use of CYP2E1 inducers may potentiate this risk in susceptible patients.
|Neuromuscular Blocking Agents||↑ neuromuscular|
|As is the case with other volatile anesthetics, ISOFLURANE increases both the intensity and duration of neuromuscular blockade induced by non-depolarizing muscle relaxants.|
|Nitrous Oxide||↓ MAC of|
|As with other halogenated volatile anesthetics, the anesthetic requirement for ISOFLURANE is decreased when administered in combination with nitrous oxide (see DOSAGE AND ADMINISTRATION).|
|Nondepolarizing relaxants||↑ action of|
|The action of nondepolarizing relaxants is augmented by ISOFLURANE. Less than the usual amounts of these drugs should be used. If the usual amounts of nondepolarizing relaxants are given, the time for recovery from neuromuscular blockade will be longer in the presence of ISOFLURANEthan during anesthesia with halothane or a balanced technique.|
|Non-selective MAO-inhibitors||Risk of crisis during the operation. It is generally recommended that treatment should be stopped two weeks prior to surgery.|
|Opioids||↓ MAC of|
|Opioids would be expected to decrease the MAC of ISOFLURANE in the same manner as with other inhalational anesthetics.|
Opioids are associated with respiratory depression. Caution should be exercised when these agents are concomitantly administered with ISOFLURANE.
|Other sedative agents||Sedative agents are associated with respiratory depression. Caution should be exercised when these agents are concomitantly administered with ISOFLURANE.|
|Succinylcholine||In patients with latent as well as overt muscular dystrophies, particularly Duchenne Muscular Dystrophy, concomitant use with succinylcholine is associated with hyperkalemia and cardiac arrhythmias (see WARNINGS AND PRECAUTIONS).|
|Sympathomimetic Agents||Alpha- and beta-sympathomimetic agents like adrenaline and noradrenaline should be used with caution during ISOFLURANE narcosis, due to a potential risk of ventricular arrhythmia.|
Increased blood solubility and uptake of the soluble anesthetics after eating prolong the rate of induction of anesthesia by slowing the rate of rise of the end-tidal (alveolar) concentration.
In a study of 12 healthy male volunteers, the isoflurane blood solubility was increased significantly (p < 0.01) 30 to 45 minutes after eating. This increase was not statistically significant 1 hour after eating.
Interactions with herbal products have not been established.
Effects on Ability to Drive and Use Machines
Patients should be advised that performance activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, may be impaired for two to four days after anesthesia with ISOFLURANE. As with other anesthetics, small changes in moods and symptoms may persist for up to six days after administration. See WARNINGS AND PRECAUTIONS, Neurologic.
Dosage and Administration
Preanesthetic medication should be selected according to the need of the individual patient, taking into account that secretions are weakly stimulated by ISOFLURANE (isoflurane) and that the heart rate tends to be increased. The use of anticholinergic drugs is a matter of choice.
Induction: Adult Patients
Induction may be achieved using ISOFLURANE alone, with oxygen or in combination with oxygen-nitrous oxide mixtures. Under these conditions coughing, breath-holding or laryngospasm may be encountered. If these difficulties are to be avoided, a hypnotic dose of an ultra-short-acting barbiturate should be used to induce unconsciousness, followed by the isoflurane mixture. It is recommended that once anesthesia has been induced with a short-acting barbiturate or other intravenous induction agent, administration of ISOFLURANEmay be initiated at a concentration of 0.5%.
In general, inspired concentrations of 1.5 to 3.0% ISOFLURANEwith 50 to 70% nitrous oxide usually produce surgical anesthesia in 7 to 10 minutes. If nitrous oxide is not used, an additional 1.0 to 1.5% ISOFLURANEmay be required for induction of anesthesia.
The administration of general anesthesia must be individualized based on the patient's response.
Surgical levels of anesthesia may be maintained with 1.0 to 2.5% ISOFLURANEwhen 50 to 70% nitrous oxide is used concomitantly. An additional 0.5-1.0% ISOFLURANEmay be required when given with oxygen alone. If added relaxation is required, supplemental doses of muscle relaxants may be used.
The level of blood pressure during maintenance is an inverse function of ISOFLURANE concentration in the absence of other complicating problems. Excessive decreases may be due to depth of anesthesia and in such instances should be corrected by lightening the level of anesthesia.
Recommended Dose and Dosage adjustment
See Table 3 below for MAC values relative to age.
|Age of Patient||With 100% Oxygen||With 70% N20|
|26 ± 4 years||1.28%||0.56%|
|44 ± 7 years||1.15%||0.50%|
|64 ± 5 years||1.05%||0.37%|
Geriatrics (> 65 years of age)
As with other agents, lesser concentrations of ISOFLURANEare normally required to maintain surgical anesthesia in elderly patients.
ISOFLURANE should be administered only by persons trained in the administration of general anesthesia (see WARNINGS AND PRECAUTIONS).
The concentration of ISOFLURANEbeing delivered from a vaporizer during anesthesia should be known. This may be accomplished by using a) flow-through vaporizers calibrated specifically for ISOFLURANEb) vaporizers from which delivered flows can easily and readily be calculated.
The delivered concentration from such a vaporizer may be calculated:
PA = Pressure of atmosphere
PV = Vapour pressure of isoflurane
FV = Flow of gas through vaporizer (mL/min)
FT = Total flow gas used (mL/min)
|For management of a suspected drug overdose, contact your regional Poison Control Centre for the most current information.|
Overdosage with ISOFLURANE (isoflurane) will generally produce marked hypotension and apnea. In the event of overdosage, or what may appear to be overdosage:
- Stop drug administration.
- Establish that the airway is clear.
- Instigate assisted or controlled ventilation with pure oxygen as the circumstances dictate.
Hypotension and respiratory depression have been observed. Close monitoring of blood pressure and respiration is recommended. Supportive measures may be necessary to correct hypotension and respiratory depression resulting from excessively deep levels of anesthesia.
Action and Clinical Pharmacology
Mechanism of Action
ISOFLURANE (isoflurane), a halogenated methyl ethyl ether, is an inhalation anesthetic used in induction and maintenance of general anesthesia.
Induction and recovery from isoflurane anesthesia are rapid due to its low solubility (blood/gas coefficient; 1:4). Isoflurane does not appear to stimulate excessive salivation or tracheo-bronchial secretions even though the pungency of isoflurane may limit the rate of induction. Pharyngeal and laryngeal reflexes are diminished quickly. The level of anesthesia with isoflurane changes rapidly, which would be predicted based upon its Oswald partition coefficients.
Isoflurane is a profound respiratory depressant. Isoflurane reduces ventilation as depth of anesthesia increases. This is a result of a decrease in tidal volume with rate of respiration remaining essentially constant. The respiratory depression is partially reversed by surgical stimulation, even at deeper levels of anesthesia. Isoflurane provokes a sigh response reminiscent of that seen with diethyl ether and enflurane.
There is a blood pressure decrease with induction of anesthesia, followed by a return to near normal with surgical stimulation. Increasing the depth of anesthesia correspondingly decreases blood pressure. Furthermore, nitrous oxide diminishes the inspired concentration of isoflurane required to reach a desired level of anesthesia and also has a favorable effect on the parameters of the anesthetic process.
With controlled ventilation and normal PaCO2, cardiac output tends to be maintained despite increasing depth of anesthesia, primarily through an increase in heart rate, which compensates for a reduction in stroke volume.
With spontaneous respiration, the resulting hypercapnea may further increase heart rate and raise cardiac output above awake levels.
The cardiac rhythm during isoflurane anesthesia is stable. Isoflurane has not been shown to sensitize the myocardial conduction system to epinephrine and does not produce serious arrhythmias in animals.
Limited data from studies in man indicates that injection subcutaneously of 0.25 mg of epinephrine (50 mL of 1:200,000 solution) does not cause ventricular arrhythmias in patients anaesthetized with isoflurane. It should be noted that doubling this dose will produce ventricular extrasystoles in about half of patients anesthetized with 1.25 MAC (Minimum Alveolar Concentration) isoflurane.
Muscle relaxation in man is adequate for intra-abdominal operations at normal levels of anesthesia. All commonly used muscle relaxants are compatible with isoflurane.
Should greater relaxation or complete paralysis be necessary, small doses of muscle relaxants may be used. Isoflurane potentiates all commonly used muscle relaxants, the effect being most profound with nondepolarizing relaxants.
Neostigmine reverses the effects of non-depolarizing muscle relaxants in the presence of isoflurane but has no effect on the relaxant properties of isoflurane itself.
The systemic metabolism of isoflurane in humans was studied in 189 patients. The fluoride levels observed indicated that isoflurane given at 0.7% concentration for 178 minutes is not subject to enzymatic degradation processes that release fluoride into the blood.
In other studies, relatively little metabolism of isoflurane occurred in the human body. The low fluoride levels are not considered likely to produce impairment of renal function.
Isolated cases of convulsions have been reported in patients receiving isoflurane. In general, isoflurane produces an EEG pattern similar to that seen with other volatile anesthetics.
A clinical trial evaluating the pharmacokinetics of inhaled anesthetics on 48 patients (16 patients received isoflurane) demonstrated that the median steady state volume of distribution of isoflurane is in average 4285 (range of 1509 to 9640) mLvapour kgbw-1. The median transport clearance from the central to the peripheral compartment for isoflurane is 30.7 (range of 15.9 to 38.7) mLvapour kg bw –1 min –1.
Partition coefficients for isoflurane at 37°C are presented in Table 3.
Relatively little metabolism of isoflurane occurs in the human body. In the postoperative period, of the isoflurane taken up, only 0.2 to 1% can be recovered as urinary metabolites. Peak serum inorganic fluoride values usually average less than 5 micromole/litre and occur about four hours after anesthesia, returning to normal levels within 24 hours. No signs of renal injury have been reported after isoflurane administration.
Special Populations and Conditions
For details, see DOSAGE AND ADMINISTRATION, Recommended Dose and Dosage Adjustment, Geriatrics (> 65 years of age).
For details, see WARNINGS AND PRECAUTIONS, Hepatic/Biliary/Pancreatic.
Storage and Stability
Store between 15 to 25°C. ISOFLURANE (isoflurane) contains no additives.
Dosage Forms, Composition and Packaging
ISOFLURANE (isoflurane) is packaged in 100 and 250 mL amber-colored bottles.
ISOFLURANE is a non-flammable inhalation anesthetic agent that is a clear, colourless, stable liquid whose purity exceeds 99.9%. The finished product is comprised only of the active drug substance, isoflurane.